Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanarus submits breast biopsy system to FDA:

This article was originally published in Clinica

Executive Summary

Sanarus Medical has filed a 510(k) approval application with the US FDA for its Core Tissue Biopsy System. The minimally invasive device is used to obtain biopsy samples from breast lesions and is based on cryosurgery and ultrasound guidance technology developed by Endocare, of Irvine, California. Sanarus of Pleasanton, California, and Endocare are jointly commercialising Endocare's cryosurgical technology for treating breast tumours and gynaecological diseases under an October 1999 agreement. Endocare also has a minority equity position in Sanarus, which plans to file additional applications in the coming months for complementary proprietary platforms for managing and treating different types of breast disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel